Practice Pearls for Optimizing MDD Treatment
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, provide their practice pearls for community psychiatrists and psychiatric nurse practitioners who care for patients with major depressive disorder (MDD) to optimize their treatment and management.
New Classes of Treatment for MDD
Experts provide an overview of novel treatments, including glutamatergic, GABAergic, and psychedelic drugs, that are either approved or currently being evaluated in clinical studies for MDD (major depressive disorders).
Treatment Switch for MDD
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss the typical strategies for switching therapies for major depressive disorder (MDD).
Practitioners discuss the need to treat patients with major depressive disorder (MDD) to a complete remission vs a decline in symptomology.
MDD Treatment: Follow-Up
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss best practices for monitoring and follow-up with patients with major depressive disorder (MDD) to ensure treatment efficacy and safety.
Approach to Treatment in Patients with MDD
Practitioners discuss their approach to treatment with their patients with major depressive disorder (MDD).
MDD as a Chronic Condition
Experts discuss how practitioners are viewing major depressive disorder (MDD) as a chronic condition vs an episodic condition.
Tailoring Treatments for Patients With MDD
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, discuss navigating the challenge of a “one size fits all approach” when treating and identifying the specific needs of patients with major depressive disorder (MDD).
Undertreatment in Patients Suffering From MDD
Practitioners discuss the rates of undertreatment in patients suffering from major depressive disorder (MDD).
Healthcare Perception of Major Depressive Disorder
Greg Mattingly, MD, and Jeremey Schreiber, MSN, PMHNP-BC, comment on the perception of major depressive disorder (MDD) within the healthcare community and the clinical and practical implications of is this condition.
Practice Pearls for Narcolepsy Management
Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, share take-home messages for the management of narcolepsy.
Case #2: 29-Year-Old Male With Type 2 Narcolepsy
Experts in sleep medicine present a case of a 29-year-old male with EDS, vivid dreams, sleep paralysis, and adult ADD, and share their initial impressions.
Case #1: 18-Year-Old Female With Type 1 Narcolepsy
Sleep experts present a case of an 18-year-old female preparing for college with EDS and cataplexy, and share their approach to treatment.
Unmet Needs in Narcolepsy Treatment
Drs Asim Roy and Richard K. Bogan discuss remaining unmet needs in the therapeutic landscape for narcolepsy.
Newer Agents for the Management of Narcolepsy
Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, comment on the evolving treatment landscape for narcolepsy and patient selection of FDA-approved agents: solriamfetol, pitolisant, and lower-sodium oxybate.
Therapeutic Options for the Management of Narcolepsy
Experts in sleep medicine share insight on initiating treatment for the management of narcolepsy.
Diagnosis of Narcolepsy and Impact on QoL
Sleep experts comment on diagnostic criteria for narcolepsy, factors that may lead to misdiagnosis, and the impact of the condition on a patient’s quality of life.
Overview and Triggers of Narcolepsy
Richard K. Bogan, MD, FCCP, FAASM, and Asim Roy, MD, provide an overview of the pathophysiology of narcolepsy and the role of orexin in regulating the sleep/wakefulness cycle.
Key Takeaways for the Management of MDD
Carmen Kosicek, MSN, PMHNP-BC; Charles Montano, MD; and Gus Alva, MD, DFAPA, provide take-home messages for the management of patients with MDD and other depressive disorders.
Unmet Needs in MDD Treatment Paradigm
Experts in psychiatry examine emerging agents and unmet needs for the management of MDD.
Impact of Different MDD Classes of Treatment on Time to Response
Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, comment on the impact of various classes of MDD treatments on time to achieve goals and/or response.
Current Challenges With MDD Treatment Options
Carmen Kosicek, MSN, PMHNP-BC, leads a discussion on the level of satisfaction for both patients and providers with currently available MDD treatment options, barriers to access, and the impact of residual symptoms on a patient’s quality of life.
Treatment Approaches for Episodic and Chronic MDD
Experts in psychiatry share their treatment approaches for the management of episodic and chronic MDD.
Treatment Options for MDD
Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, review currently available treatment options for the management of MDD and criteria used for treatment selection.
Optimizing Treatment for ADHD
“What we’re striving to do is conquer the unmet needs that are still here with treating ADHD, especially from a medication standpoint.”
Monitoring Recommendations for MDD
Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, provide advice regarding monitoring for adverse events and compliance with different classes of MDD treatment and review suggestions for follow-up and special patient populations.
Perception of MDD in the Healthcare Community
Experts in psychiatry share their thoughts on the perception of MDD within the healthcare community and the implications of this condition being viewed as chronic vs episodic.
New Biomarker Study of Rapid-Acting Treatment for Acute Depression
Apimostinel is in development for the treatment of acute depressive disorders and depression with suicidality.
“If You Ask Me My Name”
Welcome to 2023, the 25th year of Poetry of the Times with Richard Berlin, MD!
New Year, New Look
Out with the old and in with the new...
2 Clarke Drive Cranbury, NJ 08512